.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Chubb
US Department of Justice
Deloitte
Baxter
Daiichi Sankyo
Fish and Richardson
UBS
Moodys
McKesson

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022433

« Back to Dashboard

NDA 022433 describes BRILINTA, which is a drug marketed by Astrazeneca Pharms and is included in one NDA. It is available from three suppliers. There are six patents protecting this drug and two Paragraph IV challenges. Additional details are available on the BRILINTA profile page.

The generic ingredient in BRILINTA is ticagrelor. There are nineteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ticagrelor profile page.

Summary for 022433

Tradename:1
Applicant:1
Ingredient:1
Patents:6
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 022433

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BRILINTA ticagrelor TABLET;ORAL 022433 NDA AstraZeneca Pharmaceuticals LP 0186-0776 0186-0776-60 60 TABLET in 1 BOTTLE (0186-0776-60)
BRILINTA ticagrelor TABLET;ORAL 022433 NDA AstraZeneca Pharmaceuticals LP 0186-0776 0186-0776-94 1 BLISTER PACK in 1 BOX, UNIT-DOSE (0186-0776-94) > 14 TABLET in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength90MG
Approval Date:Jul 20, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 3, 2018
Regulatory Exclusivity Use:EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFRACTION
Regulatory Exclusivity Expiration:Jul 20, 2016
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Jul 15, 2018Product Flag?Substance Flag?YDelist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
US Army
Chinese Patent Office
Fuji
Queensland Health
McKesson
Colorcon
McKinsey
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot